Umbilical cord matrix stem (UCMS) cells are unique stem cells derived from Wharton's jelly, which have been shown to express genes characteristic of primitive stem cells. To test the safety of these cells, human UCMS cells were injected both intravenously and subcutaneously in large numbers into severe combined immunodeficiency (SCID) mice and multiple tissues were examined for evidence of tumor formation. UCMS cells did not form gross or histological teratomas up to 50 days posttransplantation. Next, to evaluate whether UCMS cells could selectively engraft in xenotransplanted tumors, MDA 231 cells were intravenously transplanted into SCID mice, followed by intravenous transplantation of UCMS cells 1 and 2 weeks later. UCMS cells were found near or within lung tumors but not in other tissues. Finally, UCMS cells were engineered to express human interferon beta -designated 'UCMSÀIFN-b'. UCMSÀIFN-b cells were intravenously transplanted at multiple intervals into SCID mice bearing MDA 231 tumors and their effect on tumors was examined. UCMSÀIFN-b cells significantly reduced MDA 231 tumor burden in SCID mouse lungs indicated by wet weight. These results clearly indicate safety and usability of UCMS cells in cancer gene therapy. Thus, UCMS cells can potentially be used for targeted delivery of cancer therapeutics.
Introduction
The umbilical cord contains an inexhaustible, noncontroversial source of stem cells. Worldwide, millions of umbilical cords, each containing millions of stem cells, are routinely discarded after birth. Multipotent stem cells called umbilical cord matrix stem (UCMS) cells are isolated from the mesenchyme-like cushioning material called 'Wharton's jelly' found between the vessels of the umbilical cord. 1 These cells resemble stem cells from several other sources but are also unique in some properties. The properties that promote their potential utility are the large number of cells recoverable from the umbilical cord, the noninvasive harvest following birth, and the abundant supply of umbilical cords. 2, 3 Thus, they may offer an immediate avenue for cytotherapy, when time is of the essence for such therapy, for example, in cases of malignant neoplasia. UCMS cells transplanted into rodent neurodegenerative models [4] [5] [6] have been extensively characterized 3 and they express many of the genes expressed by primitive stem cells such as embryonic stem cells (ESCs). 7 They can be differentiated into a variety of cell types including muscle, 8 cartilage, 9 bone, 9 and neural 1 cells and have been used for tissue-engineered artificial blood vessels and heart valves. 10 Previously, several types of stem cells have been shown to migrate selectively into tumors. 11, 12 Moreover, they have been engineered to secrete antitumor proteins, such as interferon beta (IFN-b), into the tumor microenvironment with favorable therapeutic effects in rodent animal models. [11] [12] [13] [14] [15] In these cases, millions of stem cells have been transplanted systemically. However, similar approaches in humans will likely require an order of magnitude more cells to achieve a comparable effect. Since large numbers of UCMS cells can be obtained in a short time, they potentially could be a solution to this dilemma.
An example of a protein successfully delivered via stem cells for an antitumor effect is IFN-b. 12, 15 This cytokine has potent proapoptotic 16, 17 and antiproliferative 18, 19 effects in vitro. Although gene therapy using bone marrow or neural stem cells has been successful in treating cancer mouse models, the preparation of these stem cells usually requires complex methods and a relatively long time.
In the present study, we investigated a key safety issue by transplanting large numbers of UCMS cells into severe combined immunodeficiency (SCID) mice to assess possible teratoma or other tumor formation. Next, we tested UCMS cells for their ability to selectively engraft in lung tumors of SCID mice. Finally, we investigated whether UCMS cells, engineered to secrete IFN-b, could reduce lung tumor burden in SCID mice. We show here that UCMS cells themselves do not form tumors; they selectively engraft in lung tumors. In addition, tumor burden in SCID mice bearing lung tumors is significantly reduced following systemic administration of human IFN-b-expressing UCMS cells.
Materials and methods
Tissue culture of human UCMS cells and MDA 231 cells Human UCMS cells were harvested following deliveries at the time of birth with the mother's consent. The methods to isolate and culture human UCMS cells were previously described. 3 MDA 231, a human breast carcinoma cell line that engrafts in the lung of nude mice 20 was maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA), 1X Pen/Strep (Invitrogen, CA) and 10% fetal bovine serum (FBS) (Mediatech, Herndon, VA) at 371C in a humidified atmosphere containing 5% carbon dioxide.
Adenoviral vectors and transduction of human UCMS cells
Since UCMS cells do not express the adenoviral receptor, fiber-modified viruses were used to allow efficient transduction. 12, 15 Recombinant adenoviral particles carrying human IFN-b were used. 12, 15 For transduction, the human UCMS cells were plated in T-75 flasks and infected when the cells reached 80-90% confluency. The cells were washed twice with DMEM without serum and incubated with DMEM containing adenovirus at 12 500 viral particles (VP) per cell (for adenovirus-IFN-b) for 4 h at 371C. The cells were cultured in UCMS media (a mixture of 56% low-glucose DMEM (Invitrogen), 37% MCBD 201 (Sigma, St Louis, MO) and 2% FBS (Mediatech, MTT 35-010-CV) containing 1 Â insulintransferrin selenium-X (ITS-X, Invitrogen, CA), 1X AlbuMAX I (Invitrogen, CA), 1X Pen/Strep (Invitrogen, CA), 10 nM dexamethasone (Sigma), 100 mM ascorbic acid 2-phosphate (Sigma), 10 ng/ml epidermal growth factor (EGF, R&D systems, Minneapolis, MN) and 10 ng/ml platelet-derived growth factor-BB (PDGF-BB, R&D systems) for 24 h and then used for transplantation studies.
IFN-b ELISA
The amount of IFN-b secreted by UCMSÀIFN-b cells into the media was quantified by a human IFN-b enzymelinked immunosorbent assay (ELISA) kit (PBL biomedical laboratories, NJ). UCMS cells were plated at 50 000 cells per well in a 12-well plate. UCMS cells were transduced with adenovirus IFN-b at various amounts (12 500, 6400 and 3200) of adenoviral particles per cell as described above. One day later, the IFN-b level in the medium was determined according to manufacturer's protocols using recombinant IFN-b as a standard.
In vitro effect of conditioned media from IFN-b-expressing UCMS cells on MDA 231 cells To condition the media, fresh media was added to subconfluent (15 000 cells/cm 2 ) UCMS cells or UCMSÀIFN-b cells for 24 h before being removed and centrifuged, and its bioactivity was examined. MDA 231 cells were plated in six-well plates at a density of 160 000 cells per well with MDA 231 growth media (DMEM and 10% FBS). After 24 h, the media was removed from all the wells and the MDA 231 media was replaced with either conditioned media from UCMS cells alone, from UCMSÀIFN-b cells or unconditioned UCMS media as a control. After 3 days, the cells were trypsinized and counted on a hemocytometer. The percentage of dead cells was estimated using trypan blue exclusion. Results were also expressed as the percentage of cell growth, calculated with the following formula: 15 (number of MDA 231 cells cultured with conditioned media on day 3Àthe number of MDA 231 cells on day 0)/(number of MDA 231 cells cultured in UCMS media on day 3Ànumber of MDA 231 cells on day 0) Â 100. Three different isolates of UCMS cells were used in separate trials and each experiment was done in triplicate.
Immunohistochemical staining
For immunofluorescence staining, tissue sections were washed with phosphate-buffered saline 0.2% containing Triton X-100 (PBS TX) and fixed with 70% ethanol and acetone (1 : 1). This was followed by washing with three changes of PBS TX. Tissue sections were blocked with 5% normal goat serum in PBS TX for 30 min, and followed by incubation with primary antibody, antihuman mitochondrial antibody (1 : 1000, Chemicon, Temecula, CA), in PBS TX overnight. The tissues were then washed three times with PBS TX and incubated with Alexa Fluor 488-conjugated secondary antibody (1 : 1000, Molecular Probes, Carlsbad, CA) for 3 h. The tissues were incubated for 30 min in Hoechst 33342 (1 : 100, Sigma) as a counterstain to label the nuclei followed by a triple rinse with PBS TX. The antigens were localized using epifluorescence microscopy (Nikon Eclipse, Boyce Scientific Inc., MO) and images were captured using a Roper Cool Snap ES camera and Metamorph 7.
Fluorescent labeling of human UCMS cells
For transplanted human UCMS cell identification, the red fluorescent dye SP-DiI (Molecular Probes) was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 5 mg/ml. SP-DiI dye was added to culture medium to a final concentration of 10 mg/ml and human UCMS cells were labeled by adding 10 ml of medium with SP-DiI in a T-75 flask for 24 h. Then, cells were washed with PBS, incubated with dye-free medium for 4 h and used for transplantations.
Evaluation of tumor formation by human UCMS cells
For the following three in vivo studies, 5-week-old female CB-17 SCID mice were obtained from Harlan laboratories (Indianapolis, IN). Mice were held for 1 week after arrival to allow them to acclimatize. They were housed in a barrier room and individual cages containing highefficiency particulate air filters. Both subcutaneous and systemic transplantation of UCMS cells suspended in 200 ml PBS were carried out under sterile conditions in a laminar flow hood in the barrier room. Animals were randomly assigned to experimental groups. The first set of mice was transplanted with 2 Â 10 6 human UCMS cells (n ¼ 5) or 1 Â 10 7 human UCMS cells (n ¼ 4) subcutaneously at the flank region. The remaining mice was transplanted with 2 Â 10 6 human UCMS cells (n ¼ 5), 3 Â 10 6 human UCMS cells (n ¼ 2) or 6.5 Â 10 6 human UCMS cells (n ¼ 1) intravenously via the lateral tail vein. All the mice were killed 50 days after transplantation by cervical dislocation. Lung, kidney and liver were collected, snap frozen in liquid nitrogen-chilled isopentane and used for immunohistochemistry studies. All in vivo experiments were carried out with proper IACUC and IBC institutional approval.
Evaluation of selective engraftment of human UCMS cells MDA 231 cells and UCMS cells were transplanted without anesthesia into the lateral tail vein using sterile conditions in a laminar flow hood in the barrier room. Animals were randomly assigned to experimental groups. For tumor induction, one set of mice was transplanted with 1 Â 10 6 MDA 231 cells (n ¼ 8). This was followed by two injections of 1 Â 10 6 fluorescently labeled UCMS cells on day 17 and day 24 after injection of MDA 231 cells. A second set of mice was transplanted with 2 Â 10 6 MDA 231 cells (n ¼ 8). This was followed by two injections of 1 Â 10 6 fluorescently labeled UCMS cells on day 11 and day 18. All the mice were killed 8 days after the last UCMS cell transplant. Other groups included mice injected with fluorescently labeled UCMS cells alone (n ¼ 4), and mice injected with sterile PBS only (n ¼ 4) as controls. Lung weights of control and tumor-bearing animals were measured to estimate tumor burden. Lungs and other organs including spleen, liver, kidney and bone marrow were also harvested as described above for immunohistochemical analysis. , n ¼ 5) were transplanted on day 8 after tumor inoculation. The UCMS cell transplant was repeated twice at 1-week intervals subsequent to the first transplant. Experimental groups also included a negative control group that received neither MDA 231 cells nor UCMS cells (n ¼ 6; PBS injections only), and a group with three weekly injections of fluorescently labeled UCMSÀIFN-b cells (0.5 Â 10 6 , n ¼ 6) into nontumor-bearing mice. All the mice were killed after 30 days by cervical dislocation. Lung weights were measured to estimate tumor burden. Lung, spleen, liver, kidney and bone marrow were harvested and subjected to histological analysis.
Statistical analysis
To evaluate the significance of overall differences in lung weights between all in vivo groups, statistical analysis was performed by analysis of variance (ANOVA). A P-value less than 0.05 was considered as significant. Following significant ANOVA, post hoc analysis using Fisher's protected least significance difference was used for multiple comparisons. Significance for post hoc testing was set at Po0.05. All the lung weight data were represented as mean7s.e. on graphs. Abbreviations: IFN-b, interferon beta; UCMS, umbilical cord matrix stem.
Human UCMS cells do not form tumors in SCID mice
All the mice were killed 50 days after UCMS cells injection. Mice appeared healthy and no clinical symptoms were found throughout the experimental period. No gross visible tumors were found around the transplantation sites or in any other regions of mice. Immunohistochemical analysis using serial sections stained by antihuman mitochondrial antibodies also failed to detect evidence of tumors in tissues such as kidney, liver and lungs (Figures 2a, b and c) . These results suggest that human UCMS cells are nontumorigenic in SCID mice and thus are potentially usable for transplantation studies. 
Engraftment of human UCMS cells in

Discussion
Here, we provide evidence that unique, primitive human stem cells that can be harvested rapidly in large numbers from umbilical cord Wharton's jelly do not themselves form tumors, and thus they are safe, practical delivery vehicles for specific genes. For the first time, we show that UCMS cells selectively engraft in tumors, can be engineered to secrete a therapeutic protein, IFN-b, and significantly reduce lung-metastasized breast carcinoma tumor burden in an animal model.
When undifferentiated ESCs are transplanted they sometimes form tumors; 21 -24 therefore, we tested whether UCMS cells might have that tendency. UCMS cells are karyotypically stable over passages and do not lose anchorage dependency, contact inhibition, or serum dependence, 2, 3 which are characteristics of cancer cells. Our in vivo findings support the in vitro published data, since they do not become tumorigenic and hence are safe from that standpoint. This is an important consideration, since these cells express some of the same primitive genes expressed by ESCs. 7 IFN-b induces apoptosis in cancer cells mainly by disrupting mitochondria and activation of the caspase cascade. 25 It also is a potent inhibitor of proliferation for many cancer cells in vitro. 18, 19 However, it cannot be used effectively as cancer therapy because the maximum tolerated dose is not high enough to attain these effects when given systemically [26] [27] [28] and it has a short half-life. Although it has been shown that serum levels of interferon delivered by engineered stem cells are insignificant in contrast to interferon given systemically, 15 the local production of IFN-b appears to be the key for tumor growth attenuation. The stem cell-based gene therapy can also avoid potential systemic adverse effects of IFN-b. Since we found no evidence of long-term persistence of UCMS cells in the evaluation of teratoma formation by stem cells (Figures 2a-c) , it is conceivable that the engrafted stem cells will not remain for a long period of time after attenuation of the tumor. In more recent work, we have engineered the UCMS cells with a thymidine kinase suicide gene as an additional safety feature (unpublished data). Taken together, our UCMS cell-based tumor-targeted IFN-b gene delivery appears to be a safe, effective and practical cancer gene therapy. The adenoviral system used to engineer the UCMS cells was fiber modified to facilitate viral entry into the cells, since some cells may not express the coxsackie virus and adenovirus receptor necessary for cell entry. 29 Our in vitro testing of this fiber-modified vector established that it was considerably more efficient than transduction with unmodified adenoviral vectors (data not shown); this is consistent with other reports. [29] [30] [31] The finding that UCMS cells administered via the tail vein exhibited a selective engraftment to the MDA 231 lung tumors of SCID mice suggests that they may respond to chemotactic signals emanating from the tumor cells. Others have reported that tumors secrete factors that recruit stromal, vascular, bone marrow and other stem cells to the tumor; theoretically the recruited cells provide a scaffolding and source of nutrients. 32, 33 Several chemokines are known to be secreted by tumors that may mediate the observed tropism, including vascular endothelial growth factor, transforming growth factor-b (TGF) family members, fibroblast growth factor (FGF) family members, platelet-derived growth factor family members, MCP-1, epidermal growth factor and interleukin-8. 34 Cells related to UCMS cells, bone marrow stromal cells, have been shown to exhibit a tropism for damaged or rapidly growing tissues as well as tumors. 12, 14, 15, 35, 36 The human UCMS cells have been characterized by gene array and cytokine array previously, 3 and express possible chemokine receptors such as SDFR1, TGFBR3 and FGFR2. Stem cell therapy for lung tumors RS Rachakatla et al
